This website is intended for healthcare professionals only.
TREATMENT OF AYA/ADULT PATIENTS WITH ALL:
Dr Nicola Gökbuget Goethe University Hospital, University Cancer Center Frankfurt, Germany
This webinar focused on the treatment of adolescent and young adult (AYA)/adult patients with ALL and the central role of asparaginase. Data from GMALL protocols were presented, which highlighted the efficacy and tolerability of asparaginase in AYA/adult patients with ALL. Asparaginase-associated toxicities in adult patients with ALL were also discussed.
Key points covered
This webinar focused on the treatment of adolescent and young adult (AYA)/adult patients with ALL and the central role of asparaginase.
Treatment of adult patients with PEG-ASP can be associated with improved survival outcomes
A rational management of ASP-associated toxicities should be established and subject to continuous
improvement and education in order to deliver optimal individualised doses for patients
Webinar Replay
Featured Speakers
Dr Nicola Gökbuget
Dr Nicola Gökbuget is the head of the study center at the department of hematology/oncology and the University Cancer Center ( in Frankfurt, Germany, and one of the UCT Scientific Task Force directors. She is also a principal investigator of the German Consortium for Translational Cancer Research and the Frankfurt Cancer Institute, a board member of the German and European LeukemiaNet as well as a founding member of the European Working Group for Adult ALL. Dr Gökbuget has been a coordinator of the German Multicenter Study Group for Adult ALL ( for over 25 years, acting as principal investigator of several clinical trials in adult ALL and related hematological diseases. She has also established a national ALL registry in Germany. In her research, Dr Gökbuget focuses on several clinical aspects of adult ALL. These include diagnosis,diagnosis,(MRD based) treatment, quality of life outcomes, late effects and the evaluation of potential new therapies and drugs, in both newly diagnosed as well as R/R settings.
